Mix and Match COVID Boosters: Time Crunch For Data Review May Mean No Advisory Committee Vote

 
• By Sarah Karlin-Smith
clock
FDA may not have time to finish reviewing heterologous booster data before the next VRBPAC • Source: Alamy

More from Vaccines

More from Pink Sheet